These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 22085233)

  • 21. Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.
    van Leeuwen PJ; Otto SJ; Kranse R; Roobol MJ; Bul M; Zhu X; de Koning H; Schröder FH
    BJU Int; 2012 Jul; 110(2):188-94. PubMed ID: 22288823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone.
    Parekh A; Chen MH; Hoffman KE; Choueiri TK; Hu JC; Bennett CL; Kattan MW; Sartor O; Stein K; Graham PL; D'Amico AV; Nguyen PL
    Urology; 2013 Jan; 81(1):130-4. PubMed ID: 23273077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.
    Elliott SP; Meng MV; Elkin EP; McAninch JW; Duchane J; Carroll PR;
    J Urol; 2007 Aug; 178(2):529-34; discussion 534. PubMed ID: 17570425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Information needs of men on androgen deprivation therapy.
    Soeyonggo T; Warde P; Fleshner N; Timilshina N; Alibhai SM
    BJU Int; 2012 May; 109(10):1503-9. PubMed ID: 21883845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
    Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
    Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.
    Dosoretz AM; Chen MH; Salenius SA; Ross RH; Dosoretz DE; Katin MJ; Mantz C; Nakfoor BM; D'Amico AV
    Cancer; 2010 Feb; 116(4):837-42. PubMed ID: 20052734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke.
    Hayes JH; Chen MH; Moran BJ; Braccioforte MH; Dosoretz DE; Salenius S; Katin MJ; Ross R; Choueiri TK; D'Amico AV
    BJU Int; 2010 Oct; 106(7):979-85. PubMed ID: 20230380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease.
    Arvold ND; Chen MH; Moul JW; Moran BJ; Dosoretz DE; Bañez LL; Katin MJ; Braccioforte MH; D'Amico AV
    J Urol; 2011 Jul; 186(1):91-6. PubMed ID: 21571341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
    Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database.
    Moreira DM; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2010 Jan; 105(1):28-33. PubMed ID: 19522861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.
    Sartor O; McLeod DG; Halabi S; Schellhammer PF; Scardino PT; D'Amico AV; Bennett C; Wei JT;
    Urology; 2010 Mar; 75(3):623-9. PubMed ID: 19589569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
    Potosky AL; Davis WW; Hoffman RM; Stanford JL; Stephenson RA; Penson DF; Harlan LC
    J Natl Cancer Inst; 2004 Sep; 96(18):1358-67. PubMed ID: 15367568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D; Tyldesley S; Pickles T;
    Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients' perceptions of quality of life after treatment for early prostate cancer.
    Clark JA; Inui TS; Silliman RA; Bokhour BG; Krasnow SH; Robinson RA; Spaulding M; Talcott JA
    J Clin Oncol; 2003 Oct; 21(20):3777-84. PubMed ID: 14551296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
    Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
    J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.